CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses
Whereas CD4 T cells conventionally mediate antitumor immunity by providing help to CD8 T cells, recent clinical studies have implied an important role for cytotoxic CD4 T cells in cancer immunity. Using an orthotopic melanoma model, we provide a detailed account of antitumoral CD4 T cell responses a...
Uloženo v:
| Vydáno v: | Science immunology Ročník 9; číslo 91; s. eadi9517 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
19.01.2024
|
| Témata: | |
| ISSN: | 2470-9468, 2470-9468 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Shrnutí: | Whereas CD4
T cells conventionally mediate antitumor immunity by providing help to CD8
T cells, recent clinical studies have implied an important role for cytotoxic CD4
T cells in cancer immunity. Using an orthotopic melanoma model, we provide a detailed account of antitumoral CD4
T cell responses and their regulation by major histocompatibility complex class II (MHC II) in the skin. Intravital imaging revealed prominent interactions of CD4
T cells with tumor debris-laden MHC II
host antigen-presenting cells that accumulated around tumor cell nests, although direct recognition of MHC II
melanoma cells alone could also promote CD4
T cell control. CD4
T cells stably suppressed or eradicated tumors even in the absence of other lymphocytes by using tumor necrosis factor-α and Fas ligand (FasL) but not perforin-mediated cytotoxicity. Interferon-γ was critical for protection, acting both directly on melanoma cells and via induction of nitric oxide synthase in myeloid cells. Our results illustrate multifaceted and context-specific aspects of MHC II-dependent CD4
T cell immunity against cutaneous melanoma, emphasizing modulation of this axis as a potential avenue for immunotherapies. |
|---|---|
| Bibliografie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ISSN: | 2470-9468 2470-9468 |
| DOI: | 10.1126/sciimmunol.adi9517 |